Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

BRCA2 promoter hypermethylation as a biomarker for the leukemic transformation of myeloproliferative neoplasms.

Epigenomics - 1 Apr 2022

Yang Can, Zhang Qingyun, Tang Xuemei, Wang Binbin, Guan Ming, Tang Gusheng, Wu Zhiyuan

Abstract excerpt

Aim: To characterize the actionable biomarker for leukemic transformation (LT) of myeloproliferative neoplasms (MPNs) at the DNA damage repair promoter methylation level. Materials & methods: Bioinformatic analysis and experimental validation were performed to identify the MPNs-LT specific biomarker out of the promoter methylation of 236 DNA damage repair genes with GSE42042 dataset and an in-house cohort of 80...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Biomarkers
Share to BRCA2 Protein
Share to DNA Methylation

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Mutation

Share to Myeloproliferative Disorders

Share to Neoplasms

Share to Promoter Regions, Genetic

Source

Identifiers

PMID: 35259923
DOI: 10.2217/epi-2022-0025

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

BRCA2 promoter hypermethylation as a biomarker for the leukemic transformation of myeloproliferative neoplasms.PMID 35259923Read ↗

Genetic changes during leukemic transformation to secondary acute myeloid leukemia from myeloproliferative neoplasms.Semantic proximity Read ↗

Emerging therapeutic targets in myeloproliferative neoplasms and peripheral T-cell leukemia and lymphomas.Semantic proximity Read ↗

Disordered epigenetic regulation in the pathophysiology of myeloproliferative neoplasms.Semantic proximity Read ↗

Importance of epigenetic changes in cancer etiology, pathogenesis, clinical profiling, and treatment: What can be learned from hematologic malignancies?Semantic proximity Read ↗

MPN: The Molecular Drivers of Disease Initiation, Progression and Transformation and their Effect on Treatment.Semantic proximity Read ↗

Addressing the challenges of accelerated and blast phase myeloproliferative neoplasms in 2022 and beyond.Semantic proximity Read ↗

Targeting DNA Methylation in Leukemia, Myelodysplastic Syndrome, and Lymphoma: A Potential Diagnostic, Prognostic, and Therapeutic ToolSemantic proximity Read ↗

Epimutational profile of hematologic malignancies as attractive target for new epigenetic therapiesSemantic proximity Read ↗

The diagnostic value of DNA methylation in leukemia: a systematic review and meta-analysis.Semantic proximity Read ↗

Genomic alterations in blast phase of BCR::ABL1-negative myeloproliferative neoplasms.Semantic proximity Read ↗

Epigenetics in the hematologic malignanciesSemantic proximity Read ↗

Gene mutations, epigenetic dysregulation, and personalized therapy in myeloid neoplasia: are we there yet?Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.